1. Introduction
Thiazolidine is a heterocyclic organic compound at position 1 with a thioether group and position 3 with an amine group. It is a five-membered saturated ring with the molecular formula of (CH2)3(NH)S. Schubert first reported the thiazolidine carboxylic acid formation as a result of the reaction of cysteine with different aldehydes [1,2]. Thiazolidine nuclei can be synthesized using various methods, as summarized in a study published in 2020 [3].
In mushrooms and vertebrates, melanin biosynthesis is catalyzed by a copper-containing enzyme, tyrosinase [4]. Tyrosinase obtained from Agaricus bisporus has shown structural similarity to mammalian tyrosinase [5,6]. This structural similarity has helped researchers conduct melanogenic studies using mushroom tyrosinase. Kojic acid, a reversible inhibitor of the tyrosinase enzyme, interacts with the binding pocket without any conformational changes in the protein. Major reported amino acids present in the active site are Val283, His263, and Phe264. Other amino residues of the active side include His244, Glu256, Asn260, and residues 279–282 and Ala286 [7,8,9].
The tyrosinase enzyme is an important enzyme responsible for the attachment of marine organisms to their substrates as well as the insect molting process. In humans, it has been found to be linked with the pathogenesis of certain neurodegenerative diseases, including Parkinson’s disease [10]. The imperative function of this enzyme is melanin biosynthesis. It activates this pathway by catalyzing two steps, indicating its importance in melanin formation. Initially, tyrosine is converted to 3,4-dihydroxyphenylalanine (
Different modifications have been made to the thiazolidine nucleus at position 2 to achieve inhibitory activity against the tyrosinase enzyme. Young Mi Ha et al. synthesized thiazolidine-4-carboxylic acid analogs with substitution at carbon number 2 as novel tyrosinase inhibitors. The structure of derivatives was rationalized using structural features of a potent inhibitor of catechol oxidase enzyme, N-phenylthiourea, along with the substrate and product of tyrosinase [20]. Some other compounds containing thiazolidine-like nuclei also possess tyrosinase inhibitory activity. These compounds have benzothiazole, benzothiazoline, benzimidazole, and thiazoline nuclei instead of thiazolidine [17,18].
The thiazolidine nucleus can be modified in different ways to obtain a wide variety of derivatives. Although many derivatives of this nucleus have been synthesized and evaluated for different biological activities, which highlight its importance [21,22], new derivatives can be designed having potential biological activities. Thiazolidine-4-carboxylic derivatives reported so far have been modified at position 2 with a free carboxylic acid group at position 4. Position 4 can be further explored for designing compounds having potential biological effects. The main aim of this research was to design and synthesize a range of 2,4-substituted thiazolidine derivatives with potential tyrosinase inhibition by modifying the 4-carboxylic acid group. The antioxidant and tyrosinase inhibitory potential of the compounds synthesized was evaluated. Molecular docking evaluation was conducted to computationally validate the findings of this study. The rational for selecting tyrosinase activity was the structural similarity of 2-(substituted phenyl) thiazolidine-4-carboxamide derivatives with tyrosine, DOPA, and N-phenylthiourea. N-phenylthiourea has shown inhibitory potential against catechol oxidase enzyme, which belongs to the same type of enzymes as tyrosinase [23]. Since reactive oxygen species can increase tyrosinase expression [24], we investigated the antioxidant potential of the synthesized compounds. Compounds having antioxidant activity may exhibit enhanced inhibitory effects on melanin synthesis.
2. Results and Discussion
2.1. Chemistry
Scheme 1 represents the two steps involved in the synthesis of thiazolidine-4-carboxamide derivatives. In the first step,
These nuclei (1–4) were used further to synthesize the carboxamide derivatives. Nuclei from the first step, 2-(substituted phenyl) thiazolidine-4-carboxylic acids (1–4), were reacted with an amine in the presence of N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC.HCl) and 4-Dimethylaminopyridine (DMAP) in dichloromethane. Stirring was carried out at room temperature for a time ranging from 4–24 h [26]. A gel-like product was obtained on reaction completion which was washed with methanol and water to obtain the product in powder form. The amines used were p-amino benzoic acid, morpholine, p-amino phenol, p-amino salicylic acid, and p-anisidine. As a result, five carboxamide derivatives were obtained numbered as a, b, c, d, and e, respectively. Nuclei with 2-methoxyphenyl (2) and 4-methoxyphenyl (4) gave a lesser yield with a longer reaction time owing to the steric hindrance, leading to the synthesis of limited derivatives, i.e., two for 2-methoxyphenyl (2a and 2d) and three derivatives in the case of 4-methoxyphenyl (4a, 4d and 4e). The yield of the final products varied from 20–72% (Table 1). In total, 14 derivatives were synthesized based on the four substituted thiazolidine nuclei and five amines. The purity of the synthesized compounds was confirmed through TLC. The chemo-informatics analysis of synthesized derivatives is presented in Table S1. Figure 1 represents the structures of all the synthesized compounds.
Derivatives synthesized were characterized using spectral data from FTIR, 1H-NMR, and 13C-NMR (Figures S1–S8). The expected stretches were observed in the spectral data of FTIR. Further, chemical shift values from proton and carbon NMR were used for structural confirmation of the planned derivatives. The chemical shift values of thiazolidine protons were compared with the NMR results of the previously reported thiazolidine-4-carboxylic acid derivatives [20]. Observed protons of the thiazolidine nucleus included 2-H, 4-H, and 5-Ha, Hb. The proton of amine (NH) mostly gives a weak signal and is usually not reported. A peak of the proton of carboxamide was observed in all the compounds, which confirmed the structure of 4-carboxamide derivatives of the thiazolidine nuclei. A singlet was observed between the ranges of 8.112–8.998 ppm.
2.2. Biological Evaluation
2.2.1. Determination of Antioxidant Activity
The 2,2-Diphenyl-1-picrylhydrazyl (DPPH) radical was used to evaluate the antioxidant potential of the synthesized compounds. Different concentrations of the samples were employed in the subject assay. The maximum antioxidant potential was shown by the compound 2d (IC50 18.17 ± 1.0 µg/mL) in comparison with the antioxidant activity of the positive control, ascorbic acid (IC50 7.83 ± 0.5 µg/mL) (Figure 2). The compound 1d also showed significant antioxidant potential with an IC50 value of 18.27 ± 1.1 µg/mL. The principle of this assay is related to the conversion of the purple-colored free radical into the pale-yellow-colored reduced form, owing to the action of a proton donating or antioxidant agent [27]. The compound with the most prominent activity (2d) possessed hydroxyls at position 3 of the ring containing the carboxamide group, whereas the methoxy group was attached to position 2 of the benzene ring. Alternatively, compound 1d also acquired hydroxy groups on both mentioned positions. These groups are categorized as strong proton donors which tend to participate in the reduction in DPPH free radicals by donating protons.
2.2.2. Tyrosinase Inhibition Studies
An evaluation of the inhibitory effect on the tyrosinase enzyme was conducted on mushroom tyrosinase. The results were compared with the competitive inhibitor of the tyrosinase enzyme, kojic acid (Table 2). Among the synthesized derivatives, the maximum inhibitory potential was observed in the case of compound 3c (IC50 16.5 ± 0.37 µM), compared with the IC50 value of the standard, kojic acid (15.9 ± 2.5 µM). Compounds 4e, 3e, 2d, and 2a also exhibited moderate activity. Compounds 3c, 3e, and 4e exhibited the presence of oxygen atoms at the para-position on both benzene rings in the form of hydroxyl and methoxy groups. The presence of oxygen atoms at these positions could be interacting with key amino acids and the copper ions of the enzyme, resulting in higher inhibitory potential. The remaining derivatives showed insignificant activity with values of IC50 varying between 98.5 ± 10.6 and 256 ± 16.3 µM.
2.3. Molecular Docking
All synthesized compounds exhibited binding affinities higher than the reference compound, kojic acid. Important amino acids of the active site, His244, Glu256, Asn260, and residues 279–282 and Ala286, were involved in the ligand–protein interactions (Table 3) (Figure S9–S23). The distance of the binding interactions varied from 1.93 Å to 5.70 Å. The highest binding affinity was exhibited by compound 3c (−8.4 Kcal/mol) (Figure 3), while the lowest binding affinity was exhibited by compounds 1e and 3e (−6.9 Kcal/mol). Kojic acid exhibited a binding affinity of −5.5 Kcal/mol. Two derivatives of the 4-hydroxy primary nucleus, 3c and 3e, with lower IC50, represent the importance of the hydroxyl group at the fourth position. This activity was decreased by the modification of the carboxylic acid group towards the carboxamide end (compound 3a), probably owing to the bulky nature of the attached group. A similar pattern was observed in compounds 1a and 1d, owing to the carboxylic acid group and higher IC50 values. Derivatives with the hydroxyl group at the second position (1a–1e) exhibited higher IC50 values. This hydroxyl group can form intramolecular hydrogen bonding with the sulfur atom of the thiazolidine ring, resulting in poor interaction with the target enzyme. This observation was supported by the results of derivatives with the 2-methoxy group (2a and 2d). The 2-methoxy derivatives showed lower IC50 values in comparison with the 2-hydroxy derivatives. All the methoxy derivatives (2a, 2d, and 4e) exhibited lower IC50 values. Some thiazolidine derivatives have been previously synthesized, which also showed tyrosinase inhibitory potential supporting the rational of this study for selecting thiazolidine nucleus [20,28]. Thiazolidine derivatives synthesized in this study are novel through the modification of the carboxamide group at the fourth position of the nucleus.
3. Materials and Methods
3.1. Instruments and Chemicals
Required chemicals and solvents were procured from Sigma-Aldrich (St. Louis, MO, USA), Merck (Kenilworth, NJ, USA), and Honeywell (Charlotte, NC, USA) with no further purification before their use. Spectrophotometric and elemental analysis was used for the characterization of the synthesized derivatives. Functional group detection was performed with a Bruker ALPHA FTIR spectrometer (Billerica, MA, USA), and structural analysis was conducted with 1HNMR and 13C NMR using a Bruker AM300 spectrophotometer (Billerica, MA, USA) with DMSO as the solvent. Melting points were also recorded with the help of the Gallenkamp melting point apparatus. Mushroom tyrosinase (EC 1.14.18.1) was purchased from Sigma-Aldrich, (St. Louis, MO, USA).
3.2. General Procedure for the Synthesis of the Thiazolidine Nucleus
A previously reported scheme was used for the synthesis of the thiazolidine nucleus [20,25]. A total of four 2-(substituted phenyl) thiazolidine-4-carboxylic acid derivatives were synthesized using differently substituted benzaldehydes.
3.2.1. 2-(2-Hydroxyphenyl)-1,3-thiazolidine-4-carboxylic Acid (1)
White solid; mp(observed): 173–175 °C; mp(lit): 173.2–175.1 °C; yield: 90%; 1H-NMR (DMSO, δ ppm): 3.009 (d, J = 14.30 Hz, 1H, 5-Ha), 3.228 (d, J = 14.30 Hz, 1H, 5-Hb), 4.235 (dd, 1J = 9.37 Hz, 2J = 5.64 Hz, 1H, 4-H), 5.699 (s, 1H, 2-H), 6.525–7.625 (m, 4H, Ar-H), 9.868 (s, 1H, Ar-2′OH).
3.2.2. 2-(2-Methoxyphenyl)-1,3-thiazolidine-4-carboxylic Acid (2)
White solid; m.p.(observed): 137–139 °C; m.p.(lit): 137.7–139.2 °C; yield: 40%; 1H-NMR (DMSO, δ ppm): 3.495 (d, J = 14.31, 1H, 5-Ha), 3.551 (d, J = 14.31, 1H, 5-Hb), 3.795 (s, 3H, Ar-2′O CH3), 3.919 (dd, 1J = 9.52, 2J = 5.39, 1H, 4-H), 5.135 (s, 1H, 2-H), 6.953–8.049 (m, 4H, Ar-H).
3.2.3. 2-(4-Hydroxyphenyl)-1,3-thiazolidine-4-carboxylic Acid (3)
White solid; m.p.(observed): 161–164 °C; m.p.(lit): 161.8–164.4 °C; yield: 55%; 1H-NMR (DMSO, δ ppm): 3.404 (d, J = 14.29, 1H, 5-Ha), 3.621 (d, J = 14.29, 1H, 5-Hb), 3.693 (dd, 1J = 9.37, 2J = 5.64, 1H, 4-H), 5.236 (s, 1H, 2-H), 6.653–8.049 (m, 4H, Ar-H), 9.563 (s, 1H, Ar-4′OH).
3.2.4. 2-(4-Methoxyphenyl)-1,3-thiazolidine-4-carboxylic Acid (4)
White solid; m.p.(observed): 157–158 °C; m.p.(lit): 157.6–158.2 °C; yield: 45%; 1H-NMR (DMSO, δ ppm): 3.494 (d, J = 14.31, 1H, 5-Ha), 3.549 (d, J = 14.31, 1H, 5-Hb), 3.747 (s, 3H, Ar-4′OCH3), 3.887 (dd, 1J = 9.52, 2J = 5.39, 1H, 4-H), 5.147 (s, 1H, 2-H), 6.895–8.049 (m, 4H, Ar-H).
3.3. General Scheme for the Synthesis of Carboxamide Derivatives from Thiazolidine Nucleus
Carboxamide derivatives were synthesized from the thiazolidine nucleus by reacting with various amines [26]. 2-(substituted phenyl) thiazolidine-4-carboxylic acid (0.98 mmol), amine (1.12 mmol), DMAP (1.09 mmol), and EDC.HCl (1.08 mmol) were mixed in dichloromethane (2 mL). Then, stirring for 4 h was carried out at room temperature. The product was obtained in the form of a hard gel. This gel-type product was washed with methanol and water to obtain a purified product in the form of a powder.
3.3.1. 4-[2-(2-Hydroxyphenyl)-1,3-thiazolidine-4-carbonyl]-aminobenzoic Acid (1a)
Yellow solid; yield: 54%; m.p.: 135–136 °C; IR cm−1: 3500 (O-H), 3100 (N-H stretch), 1600 (C=O), 1500 (N-H bend), 1470 (C=C); 1H-NMR (DMSO, δ ppm): 3.009 (d, J = 14.30 Hz, 1H, 5-Ha), 3.228 (d, J = 14.30 Hz, 1H, 5-Hb), 4.235 (dd, 1J = 9.37 Hz, 2J = 5.64 Hz, 1H, 4-H), 5.699 (s, 1H, 2-H), 6.525–7.625 (m, 8H, Ar-H), 8.141 (s, 1H, amide-NH), 9.868 (s, 1H, Ar-2′OH), 11.295 (s, 1H, 4″COOH); 13C-NMR (DMSO, 100 MHz, δ ppm): 172.4 (CO-NH), 168.2 (COOH), 161.0 (C-2′), 136.4 (C-1′), 132.5 (C-3″, C-5″), 130.2 (C-4′), 127.4 (C-5′), 126.5 (C-1′), 126.0 (C-6′), 125.7 (C-4″), 119.0 (C-2″, C-6″), 118.2 (C-3′), 66.2 (C-2), 56.2 (C-4), 32.4 (C-5); Anal. Calcd. for C17H16N2O4S: C, 58.88; H, 3.95; N, 7.92; O, 17.96; S, 10.201. Found: C, 58.15; H, 3.30; N, 7.22; O, 18.40; S, 9.25.
3.3.2. [2-(2-Hydroxyphenyl)-1,3-thiazolidin-4-yl](morpholin-4-yl)-methanone (1b)
Orange solid; yield: 68%; m.p.: 128–129 °C; IR cm−1: 3600 (O-H), 3120 (N-H stretch), 1640 (C=O), 1590 (N-H bend), 1448 (C=C); 1H-NMR (DMSO, δ ppm): 3.393 (d, J = 14.34, 1H, 5-Ha), 3.598 (d, J = 14.34, 1H, 5-Hb), 3.624 (m, 8H, CH2), 3.712 (dd, 1J =9.37, 2J = 5.64, 1H, 4-H), 5.436 (s, 1H, 2-H), 6.658–7.398 (m, 8H, Ar-H); 13C-NMR (DMSO, 100 MHz, δ ppm): 170.2 (CO-NH), 160.5 (C-2′), 130.2 (C-4′), 129.5 (C-5′), 129.0 (C-1′), 128.6 (C-6′), 117.2 (C-3′), 66.8 (C-3″, C-5″), 64.8 (C-2), 57.4 (C-4), 44.5 (C-2″, C-6″), 31.6 (C-5); Anal. Calcd. for C14H18N2O3S: C, 57.12; H, 5.95; N, 8.85; O, 16.31; S, 9.74. Found: C, 56.95; H, 6.05; N, 8.45; O, 16.35; S, 9.80.
3.3.3. 2-(2-Hydroxyphenyl)-N-(4-hydroxyphenyl)-1,3-thiazolidine-4-carboxamide (1c)
Black solid; yield: 45%; m.p.: 109–111 °C; IR cm−1: 3530 (O-H), 3400 (N-H stretch), 1650(C=O), 1500 (N-H bend), 1410 (C=C); 1H-NMR (DMSO, δ ppm): 3.408 (d, J = 14.31, 1H, 5-Ha), 3.610 (d, J = 14.31, 1H, 5-Hb), 3.717 (dd, 1J = 9.37, 2J = 5.64, 1H, 4-H), 5.437 (s, 1H, 2-H), 6.658–7.398 (m, 8H, Ar-H), 8.518 (s, 1H, amide-NH), 9.218 (s, 1H, Ar-2′OH), 9.965 (s, 1H, Ar-4″OH); 13C-NMR (DMSO, 100 MHz, δ ppm): 174.8 (CO-NH), 162.0 (C-2′), 158.4 (C-4″), 137.8 (C-1″), 130.4 (C-4′), 128.4 (C-5′), 127.0 (C-1′), 125.8 (C-6′), 120.5 (C-5″, C-6″), 116.5 (C-3′), 113.2 (C-3″, C-5″), 66.2 (C-2), 55.4 (C-4), 30.6 (C-5). Anal. Calcd. for C16H16N2O3S: C, 59.85; H, 4.95; N, 9.12; O, 15.17; S, 9.03. Found: C, 59.70; H, 4.02; N, 9.50; O, 15.20; S, 10.10.
3.3.4. 2-Hydroxy-4-[2-(2-hydroxyphenyl)-1,3-thiazolidine-4-carbonyl]-aminobenzoic Acid (1d)
Yellow solid; yield: 68%; m.p.: 134–135 °C; IR cm−1: 3530 (O-H), 3150 (N-H stretch), 1643 (C=O), 1590 (N-H bend), 1400 (C=C); 1H-NMR (DMSO, δ ppm): 3.406 (d, J = 14.29, 1H, 5-Ha), 3.623 (d, J = 14.29, 1H, 5-Hb), 3.758 (dd, 1J = 9.37, 2J = 5.64, 1H, 4-H), 5.437 (s, 1H, 2-H), 6.308–8.023 (m, 8H, Ar-H), 8.123 (s, 1H, amide-NH), 9.225 (s, 1H, Ar-2′OH), 9.995 (s, 1H, Ar-3″OH), 11.598 (s, 1H, 4″-COOH); 13C-NMR (DMSO, 100 MHz, δ ppm): 173.5 (CO-NH),170.8 (COOH), 165.3 (C-3″), 161.0 (C-2′), 140.2 (C-1″), 133.4 (C-5″), 129.9 (C-4′), 128.8 (C-5′), 128.0 (C-1′), 126.0 (C-6′), 118.5 (C-6″), 115.8 (C-3′), 111.8 (C-4″), 101.1 (C-2″), 66.4 (C-2), 55.2 (C-4), 31.1 (C-5); Anal. Calcd. for C17H16N2O5S: C, 57.22; H, 5.04; N, 8.12; O, 21.10; S, 9.15. Found: C, 57.60; H, 5.45; N, 8.65; O, 21.18; S, 9.83.
3.3.5. 2-(2-Hydroxyphenyl)-N-(4-methoxyphenyl)-1,3-thiazolidine-4-carboxamide (1e)
Yellow solid; yield: 60%; m.p.: 83–84 °C; IR cm−1: 3600 (O-H), 3100 (N-H stretch), 1670 (C=O), 1490 (N-H bend), 1450 (C=C); 1H-NMR (DMSO, δ ppm): 3.152 (d, J = 14.04, 1H, 5-Ha), 3.324 (d, J = 14.04, 1H, 5-Hb), 3.797(s, 3H, 4″-OCH3), 4.358 (dd, 1J = 9.52, 2J = 5.39, 1H, 4-H), 5.298 (s, 1H, 2-H), 6.935–7.633 (m, 8H, Ar-H), 8.425 (s, 1H, amide-NH), 9.525 (s, 1H, Ar-2′OH); 13C-NMR (DMSO, 100 MHz, δ ppm): 173.6 (CO-NH), 162.0 (C-2′), 155.8 (C-4″), 138.4 (C-1″), 129.2 (C-4′), 128.4 (C-5′), 128.0 (C-1′), 127.2 (C-6′), 121.5 (C-2″. C-6″), 116.9 (C-3′), 113.5 (C-3″, C-5″), 66.5 (C-2), 56.6 (C-4), 55.0 (4′-OCH3), 31.8 (C-5). Anal. Calcd. for C17H18N2O3S: C, 61.80; H, 4.95; N, 7.98; O, 14.53; S, 10.03. Found: C, 61.75; H, 4.45; N, 7.42; O, 14.48; S, 10.60.
3.3.6. 4-[2-(2-Methoxyphenyl)-1,3-thiazolidine-4-carbonyl]-aminobenzoic Acid (2a)
White solid; yield: 20%; m.p.: 116–117 °C; IR cm−1: 3500 (O-H), 3220 (N-H stretch), 1600 (C=O), 1498 (N-H bend), 1380 (C=C); 1H-NMR (DMSO, δ ppm): 3.495 (d, J = 14.31, 1H, 5-Ha), 3.551 (d, J = 14.31, 1H, 5-Hb), 3.795 (s, 3H, Ar-2′O CH3), 3.919 (dd, 1J = 9.52, 2J = 5.39, 1H, 4-H), 5.135 (s, 1H, 2-H), 6.953–8.049 (m, 8H, Ar-H), 8.235 (s, 1H, amide-NH), 11.285 (s, 1H, 4″-COOH); 13C-NMR (DMSO, 100 MHz, δ ppm): 170.2 (CO-NH), 165.1 (COOH), 155.3 (C-2′), 138.4 (C-1″), 131.5 (C-3″, C-5″), 129.4 (C-4′), 128.5 (C-5′), 128.0 (C-1′), 127.8 (C-6′), 127.0 (C-4″), 117.9 (C-2″, C-6″), 114.8 (C-3′), 66.2 (C-2), 56.8 (C-4), 55.0 (2′-OCH3), 30.9 (C-5). Anal. Calcd. for C18H18N2O4S: C, 61.14; H, 4.92; N, 8.03; O, 17.86; S, 9.02. Found: C, 61.20; H, 4.95; N, 8.45; O, 17.90; S, 8.88.
3.3.7. 2-Hydroxy-4-[2-(2-methoxyphenyl)-1,3-thiazolidine-4-carbonyl]-aminobenzoic Acid (2d)
White solid; yield: 25%; m.p.: 112–113 °C; IR cm−1: 3510 (O-H), 3300 (N-H stretch), 1660 (C=O), 1489 (N-H bend), 1386 (C=C); 1H-NMR (DMSO, δ ppm): 3.496 (d, J = 14.31, 1H, 5-Ha), 3.551 (d, J = 14.31, 1H, 5-Hb), 3.795 (s, 3H, Ar-2′O CH3), 3.888 (dd, 1J = 9.52, 2J = 5.39, 1H, 4-H), 5.135 (s, 1H, 2-H), 6.953–7.395 (m, 8H, Ar-H), 8.586 (s, 1H, amide-NH), 9.228 (s, 1H, Ar-3″OH), 11.298 (s, 1H, 4″-COOH); 13C-NMR (DMSO, 100 MHz, δ ppm): 174.2 (CO-NH), 172.3 (COOH), 162.3 (C-3″), 158.3 (C-2′), 140.3 (C-1″), 132.3 (C-5″), 130.4 (C-4′), 128.5 (C-5′), 128.0 (C-1′), 126.8 (C-6′), 118.9 (C-6″), 114.5 (C-3′), 110.2 (C-4″), 100.4 (C-2″), 64.2 (C-2), 56.5 (C-4), 54.0 (2′-OCH3), 31.2 (C-5); Anal. Calcd. for C18H18N2O5S: C, 60.12; H, 5.02; N, 8.22; O, 20.13; S, 9.42. Found: C, 60.22; H, 5.22; N, 8.42; O, 21.24; S, 8.42.
3.3.8. 4-[2-(4-Hydroxyphenyl)-1,3-thiazolidine-4-carbonyl]-aminobenzoic Acid (3a)
Yellow solid; yield: 72%; m.p.: 164–166 °C; IR cm−1: 3550 (O-H), 3000 (N-H stretch), 1597 (C=O), 1508 (N-H bend), 1450 (C=C); 1H-NMR (DMSO, δ ppm): 3.404 (d, J = 14.29, 1H, 5-Ha), 3.621 (d, J = 14.29, 1H, 5-Hb), 3.693 (dd, 1J = 9.37, 2J = 5.64, 1H, 4-H), 5.236 (s, 1H, 2-H), 6.653–8.049 (m, 8H, Ar-H), 8.998 (s, 1H, amide-NH), 9.563 (s, 1H, Ar-4′OH), 12.004 (s, 1H, 4″COOH); 13C-NMR (DMSO, 100 MHz, δ ppm): 173.7 (CO-NH), 164.5 (COOH), 159.4 (C-4′), 138.4 (C-1″), 135.1 (C-1′), 131.2 (C-3″, C-5″), 127.2 (C-2′, C-6′), 125.1 (C-4″), 117.8 (C-2″, C-6”), 114.7 (C-3′, C-5′), 63.2 (C-2), 54.6 (C-4), 32.6 (C-5); Anal. Calcd. for C17H16N2O4S: C, 60.12; H, 5.14; N, 7.95; O, 18.58; S, 8.92. Found: C, 60.10; H, 5.40; N, 7.92; O, 18.40; S, 8.45.
3.3.9. N,2-Bis(4-hydroxyphenyl)-1,3-thiazolidine-4-carboxamide (3c)
Black solid; yield: 68%; m.p.: 174–176 °C; IR cm−1: 3580 (O-H), 3050 (N-H stretch), 1640 (C=O), 1512 (N-H bend), 1400 (C=C); 1H-NMR (DMSO, δ ppm): 3.408 (d, J = 14.30, 1H, 5-Ha), 3.615 (d, J = 14.30, 1H, 5-Hb), 3.692 (dd, 1J = 9.37, 2J = 5.64, 1H, 4-H), 5.326 (s, 1H, 2-H), 6.653–7.278 (m, 8H, Ar-H), 8.112 (s, 1H, amide-NH), 9.158 (s, 1H, Ar-4′OH), 9.998 (s, 1H, 4″OH); 13C-NMR (DMSO, 100 MHz, δ ppm): 170.2 (CO-NH), 157.5 (C-4′), 138.4 (C-1″), 134.2 (C-1′), 128.7 (C-2′, C-6′), 120.8 (C-2″, C-6″), 116.2 (C-3′, C5′), 114.2 (C-3″, C-5″), 64.3 (C-2), 55.6 (C-4), 32.4 (C-5); Anal. Calcd. for C16H16N2O3S: C, 59.89; H, 4.92; N, 9.12; O, 15.17; S, 9.24. Found: C, 59.95; H, 4.98; N, 9.22; O, 15.03; S, 10.02.
3.3.10. 2-Hydroxy-4-[2-(4-hydroxyphenyl)-1,3-thiazolidine-4-carbonyl]-aminobenzoic Acid (3d)
Yellow solid; yield: 68%; m.p.: 130–131 °C; IR cm−1: 3500 (O-H), 3100 (N-H stretch), 1600 (C=O), 1560 (N-H bend), 1450 (C=C); 1H-NMR (DMSO, δ ppm): 3.405 (d, J = 14.29, 1H, 5-Ha), 3.622 (d, J = 14.29, 1H, 5-Hb), 3.696 (dd, 1J = 9.37, 2J = 5.64, 1H, 4-H), 5.327 (s, 1H, 2-H), 6.307–8.023 (m, 8H, Ar-H), 8.534 (s, 1H, amide-NH), 9.125 (s, 1H, Ar-4′OH), 9.893 (s, 1H, Ar-3″OH), 11.518 (s, 1H, 4″COOH); 13C-NMR (DMSO, 100 MHz, δ ppm): 173.2 (CO-NH), 170.1 (COOH), 162.5 (C-3″), 158.4 (C-4′), 139.3 (C-1″), 135.8 (C-1′), 130.5 (C-5″), 128.8 (C-2′, C-6′), 118.0 (C-6″), 114.4 (C-3′, C-5′), 109.3 (C-4″), 101.2 (C-2″), 64.2 (C-2), 54.5 (C-4), 33.6 (C-5); Anal. Calcd. for C17H16N2O5S: C, 57.12; H, 5.15; N, 8.32; O, 21.95; S, 9.12. Found: C, 57.50; H, 5.35; N, 8.70; O, 21.80; S, 9.05.
3.3.11. 2-(4-Hydroxyphenyl)-N-(4-methoxyphenyl)-1,3-thiazolidine-4-carboxamide (3e)
Brown solid; yield: 65%; m.p.: 115–117 °C; IR cm−1: 3500 (O-H), 3100 (N-H stretch), 1600 (C=O), 1550 (N-H bend), 1440 (C=C); 1H-NMR (DMSO, δ ppm): 3.445 (d, J = 14.33, 1H, 5-Ha), 3.539 (d, J = 14.33, 1H, 5-Hb), 3.715 (s, 3H, 4″OCH3), 3.825 (dd, 1J = 9.52, 2J = 5.39, 1H, 4-H), 5.154 (s, 1H, 2-H), 6.653–7.275 (m, 8H, Ar-H), 8.224 (s, 1H, amide-NH), 9.212 (s, 1H, Ar-4′OH); 13C-NMR (DMSO, 100 MHz, δ ppm): 172.2 (COOH), 157.7 (C-4″), 155.4 (C-4′), 137.8 (C-1″), 134.2 (C-1′), 128.8 (C-2′, C-6′), 121.5 (C-2″, C-6″), 118.4 (C3′, C-5′), 115.2 (C-3″, C-5″), 64.2 (C-2), 57.2 (C-4), 55.0 (4″-OCH3), 32.2 (C-5); Anal. Calcd. for C17H18N2O3S: C, 61.80; H, 4.49; N, 9.05; O, 14.53; S, 10.12. Found: C, 61.78; H, 4.30; N, 9.35; O, 14.22; S, 10.63.
3.3.12. 4-[2-(4-Methoxyphenyl)-1,3-thiazolidine-4-carbonyl]-aminobenzoic Acid (4a)
Yellow solid; yield: 60%; m.p.: 94–95 °C; IR cm−1: 3610 (O-H), 3200 (N-H stretch), 1590 (C=O), 1550 (N-H bend), 1420 (C=C); 1H-NMR (DMSO, δ ppm): 3.494 (d, J = 14.31, 1H, 5-Ha), 3.549 (d, J = 14.31, 1H, 5-Hb), 3.747 (s, 3H, Ar-4′OCH3), 3.887 (dd, 1J = 9.52, 2J = 5.39, 1H, 4-H), 5.147 (s, 1H, 2-H), 6.895–8.049 (m, 8H, Ar-H), 8.152 (s, 1H, amide-NH), 11.892 (s, 1H, 4″COOH); 13C-NMR (DMSO, 100 MHz, δ ppm): 171.8 (CO-NH), 167.8 (COOH), 160.9 (C-4′), 136.2 (C-1″), 135.0 (C-1′), 131.4 (C-3″, C-5″), 129.4 (C-2′, C-6′), 128.2 (C-4″), 118.8 (C-2″, C-6″), 113.3 (C-3′, C-5′), 64.2 (C-2), 56.6 (4′-OCH3), 54.0 (C-4), 32.6 (C-5). Anal. Calcd. for, C18H18N2O4S: C, 59.92; H, 4.80; N, 8.13; O, 17.86; S, 9.21. Found: C, 59.75; H, 4.92; N, 8.66; O, 17.70; S, 8.84.
3.3.13. 2-Hydroxy-4-[2-(4-methoxyphenyl)-1,3-thiazolidine-4-carbonyl]-aminobenzoic Acid (4d)
White solid; yield: 66%; m.p.: 109–110 °C; IR cm−1: 3600 (O-H), 3120 (N-H stretch), 1645 (C=O), 1511 (N-H bend), 1420 (C=C); 1H-NMR (DMSO, δ ppm): 3.461 (d, J = 14.31, 1H, 5-Ha), 3.552 (d, J = 14.31, 1H, 5-Hb), 3.744 (s, 3H, Ar-4′OCH3), 3.861 (dd, 1J = 9.52, 2J = 5.39, 1H, 4-H), 5.148 (s, 1H, 2-H), 6.307–8.023 (m, 8H, Ar-H), 8.212 (s, 1H, amide-NH), 9.518 (s, 1H, Ar-3″OH), 12.001 (s, 1H, 4″-COOH); 13C-NMR (DMSO, 100 MHz, δ ppm): 171.2 (CO-NH), 170.1 (COOH), 163.4 (C-3″), 159.2 (C-4′), 135.4 (C-1″), 135.1 (C-1′), 130.7 (C-5″), 126.8 (C-2′, C-6′), 116.2 (C-6″), 114.0 (C-3′, C-5′), 110.1 (C-4″), 100.4 (C-2″), 64.8 (C-2), 54.8 (C-4), 52.4 (4-OCH3), 31.6 (C-5); Anal. Calcd. for C18H18N2O5S: C, 60.02; H, 5.11; N, 8.24; O, 20.98; S, 9.11. Found: C, 60.29; H, 5.22; N, 8.38; O, 21.40; S, 8.16.
3.3.14. N,2-Bis(4-methoxyphenyl)-1,3-thiazolidine-4-carboxamide (4e)
Brown solid; yield: 66%; m.p.: 129–131 °C; IR cm−1: 3150 (N-H stretch), 1600 (C=O), 1500 (N-H bend), 1410 (C=C); 1H-NMR (DMSO, δ ppm): 3.445 (d, J = 14.33, 1H, 5-Ha), 3.545 (d, J = 14.33, 1H, 5-Hb), 3.742 (s, 3H, Ar-2′OCH3), 3.763 (s, 3H, Ar-4″OCH3), 3.825 (dd, 1J = 9.52, 2J = 5.39, 1H, 4-H), 5.142 (s, 1H, 2-H), 6.637–7.297 (m, 8H, Ar-H), 8.512 (s, 1H, amide-NH); 13C-NMR (DMSO, 100 MHz, δ ppm): 171.5 (CO-NH), 159.8 (C-4′), 138.1 (C-1″), 135.0 (C-1′), 127.7 (C-2′, C-6′), 121.5 (C-2″, C-6″), 115.5 (C-3″, C-5″), 114.1 (C-3′, C-5′), 64.2 (C-2), 56.5 (C-4), 56.0(4′-OCH3, 4″-OCH3), 32.6 (C-5); Anal. Calcd. for C18H20N2O3S: C, 61.94; H, 4.95; N, 7.89; O, 13.94; S, 8.85. Found: C, 61.85; H, 4.50; N, 7.42; O, 13.78; S, 9.22.
3.4. Biological Evaluation
3.4.1. Determination of Antioxidant Activity
The synthesized compounds were evaluated for their antioxidant activity by measuring their ability to scavenge DPPH free radicals. A previously described protocol was followed for this purpose [27]. An amount of 20 µL of each of the four different dilutions of test samples (200, 66.66, 22.22, and 7.41 µg/mL) was added to 96-well plates containing 180 µL of DPPH solution. The absorbance at 517 nm was determined after incubating for 30 min at 37 °C. Ascorbic acid (1 mg/mL DMSO) was used as the positive control, and the assay was performed in triplicate. The IC50 values were also calculated using the % of inhibitions at different concentrations using Table Curve 2D Windows version 4.07.
3.4.2. Inhibitory Assay against Tyrosinase Enzyme
A tyrosinase inhibitory assay was conducted with the mushroom tyrosinase enzyme [29,30,31]. An amount of 20 µL of mushroom tyrosinase (30 U/mL) was combined with 140 µL (20 mM, pH 6.8) of phosphate buffer. An amount of 20 µL of inhibitor solution was added to a 96-well microplate. Then pre-incubation at room temperature was conducted for 10 min. A solution of
The absorbance of dopa-chrome was measured at 492 nm using a microplate reader (OPTIMax, Tunable, San Jose, CA, USA). Phosphate buffer and kojic acid were used as the negative control and the reference inhibitor, respectively. The IC50 values were used to express the extent of inhibition. The experiments were performed in triplicate for each concentration.
3.5. In Silico Studies
Chemo-informatic analysis was performed using Molinspiration and ChemSketch [32]. Molecular docking was conducted using PyRX v0.8 [33]. A tyrosinase enzyme of mushroom origin having the PDB ID: 2Y9X was acquired from the RCSB Protein DataBank Site [7]. The search space for molecular docking was adjusted to the center with X: −7.4, Y: −23.5, and Z: −32.5 and dimensions of X: 61.33, Y: 57.4, and Z: 63. Discovery studio was used for the visualization of ‘.pdb’ files, cleaning of the protein molecule, and visualization of ligand–protein interactions in 3D and 2D. The structures of the ligands were drawn using ChemDraw v16 and converted into pdb files using Chem3D v16 [34].
4. Conclusions
This study presents the design and synthesis of a series of thiazolidine derivatives. The synthesized compounds were screened for their potential biological activity using molecular docking and in vitro antioxidant and tyrosinase inhibitory assays. were conducted to identify the potential biological activity of the synthesized compounds. Compound 2d showed the maximum antioxidant potential (18.17 ± 1.0 µg/mL). In the tyrosine inhibition assay, compound 3c exhibited significant activity with an IC50 value of 16.5 ± 0.37 µM. Molecular docking analysis led to an overview of the structural properties that can affect ligand–protein interactions. Hydrophobic interactions and hydrogen bonding were found to play a significant role. Compounds 4e, 3e, 2d, and 2a can also serve as leads for designing tyrosinase inhibitors by further optimizing their structures. These inhibitors have the potential to be used for treating tyrosinase-related disorders in various fields, including medicine, food, agriculture, and cosmetics. Future prospects may include in vivo analyses, such as skin depigmentation assay, and mechanism-based studies for evaluating the effects of the synthesized compounds in biological systems. Being novel in nature, these compounds can also be screened for other biological activities.
Conceptualization, H.N. and M.K.Z.; methodology, M.K.Z., Z.A. and H.N.; validation, Z.A. and N.A.; formal analysis, M.A.A.-M., M.A. (Mohammed Aufy) and M.A. (Madiha Ahmed); investigation, M.K.Z.; resources, Z.A., N.A. and M.A.A.-M.; data curation, M.A. (Madiha Ahmed); writing—original draft preparation, M.K.Z. and H.N.; writing—review and editing, M.A. (Madiha Ahmed) and M.A. (Mohammed Aufy); supervision, H.N.; project administration, Z.A. and N.A.; funding acquisition, M.A.A.-M. and M.A. (Mohammed Aufy). All authors have read and agreed to the published version of the manuscript.
Not applicable.
Not applicable.
Data are contained within the article and the
The authors extend their appreciation to the Researchers Supporting Project, number (RSPD2023R725), King Saud University, Riyadh, Saudi Arabia, for the funding of this research.
The authors declare no conflict of interest.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Scheme 1. Synthetic route to 2-(substituted phenyl)-1,3-thiazolidine-4-carboxamide.
Figure 2. The IC50 values of synthesized compounds in the DPPH free radical scavenging assay. The results are presented as mean ± SD. P.C. stands for positive control (ascorbic acid).
Figure 3. Binding interactions between derivative 3c and mushroom tyrosinase active site (PDB-ID 2Y9X). (a) Binding conformation of compound 3c in 3D along with the binding interaction of the protein–ligand complex. (b) Interaction patterns in 2D indicating the type and distance of the interaction. Legend indicates various types of binding interactions present.
Physical properties of synthesized derivatives.
Compound | Physical State | Color | Molecular Formula | Melting Point (°C) | %Yield |
---|---|---|---|---|---|
1a | Solid | Yellow | C17H16N2O4S | 135–136 | 54 |
1b | Solid | Orange | C14H18N2O3S | 128–129 | 68 |
1c | Solid | Black | C16H16N2O3S | 109–111 | 45 |
1d | Solid | Yellow | C17H16N2O5S | 134–135 | 68 |
1e | Solid | Yellow | C17H18N2O3S | 83–84 | 60 |
2a | Solid | White | C18H18N2O4S | 116–117 | 20 |
2d | Solid | White | C18H18N2O5S | 112–113 | 25 |
3a | Solid | Yellow | C17H16N2O4S | 164–166 | 72 |
3c | Solid | Black | C16H16N2O3S | 174–176 | 68 |
3d | Solid | Yellow | C17H16N2O5S | 130–131 | 68 |
3e | Solid | Brown | C17H18N2O3S | 115–117 | 65 |
4a | Solid | Yellow | C18H18N2O4S | 94–95 | 60 |
4d | Solid | White | C18H18N2O5S | 109–110 | 66 |
4e | Solid | Brown | C18H20N2O3S | 129–131 | 66 |
Inhibitory activity of synthesized derivatives against the tyrosinase enzyme.
Compound | IC50 ± SEM (µM) |
---|---|
1a | 98.5 ± 10.6 |
1b | 131.5 ± 20.3 |
1c | ND |
1d | 256.4 ± 16.3 |
1e | 109.3 ± 13.4 |
2a | 49.8 ± 11.9 |
2d | 46.6 ± 7.6 |
3a | 186.3 ± 18.3 |
3c | 16.5 ± 0.37 |
3d | ND |
3e | 44.8 ± 6.2 |
4a | ND |
4d | ND |
4e | 41.6 ± 10.4 |
Kojic acid | 15.9 ± 2.5 |
ND: Not determined.
Binding affinities and respective amino acids interacting with the ligand (synthesized derivatives).
Protein Target | Ligand | Binding Affinity (Kcal/mol) † | Amino Acids Involved |
---|---|---|---|
Mushroom Tyrosinase |
1a | −7.3 | HIS61, HIS259, PRO277, SER282, VAL283 |
1b | −7.4 | HIS263, PRO277, MET280, SER282, VAL283, ALA286 | |
1c | −8.3 | VAL248, ASN260, HIS263, PHE264, VAL283, ALA286 | |
1d | −7.5 | HIS61, HIS259, HIS263, PRO277, MET280, SER282, VAL283 | |
1e | −6.9 | PRO277, HIS259, HIS263, VAL283 | |
2a | −7.3 | HIS61, HIS259, PRO277, SER282, VAL282 | |
2d | −7.5 | HIS61, HIS259, HIS263, PRO277, SER282, VAL283 | |
3a | −7.4 | HIS244, VAL248, VAL283 | |
3c | −8.4 | VAL248, ASN260, HIS263, PHE264, VAL283, ALA286 | |
3d | −7.1 | HIS61, HIS259, ASN260, HIS263, PRO277, SER282, VAL283 | |
3e | −6.9 | HIS244, VAL248, HIS263, VAL283, GLU322 | |
4a | −7.4 | HIS244, VAL248, HIS263, MET280, SER282, VAL283, GLU322 | |
4d | −7 | HIS61, HIS259, HIS263, PRO277, MET280, SER282, VAL283 | |
4e | −7.1 | HIS244, GLY245, VAL248, HIS263, VAL283 | |
Kojic acid | −5.6 | HIS263, VAL283, ALA286 |
† All values are expressed as the mean of triplicate determinations.
Supplementary Materials
The following supporting information can be downloaded at:
References
1. Schubert, M.P. Compounds of thiol acids with aldehydes. J. Biol. Chem.; 1936; 114, pp. 341-350. [DOI: https://dx.doi.org/10.1016/S0021-9258(20)65226-7]
2. Nawar, F.; Al-Asadi, R.; Abid, D. Synthesis, Antibacterial Activity and DFT Calculations of Some Thiazolidine-4-Carboxylic acid Derivatives and Their Complexes with Cu (II), Fe (II) and VO (II). Egypt. J. Chem.; 2020; 63, pp. 349-362. [DOI: https://dx.doi.org/10.21608/ejchem.2019.16096.1986]
3. Sahiba, N.; Sethiya, A.; Soni, J.; Agarwal, D.K.; Agarwal, S. Saturated five-membered thiazolidines and their derivatives: From synthesis to biological applications. Top. Curr. Chem.; 2020; 378, 34. [DOI: https://dx.doi.org/10.1007/s41061-020-0298-4] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32206929]
4. Şöhretoğlu, D.; Sari, S.; Barut, B.; Özel, A. Tyrosinase inhibition by some flavonoids: Inhibitory activity, mechanism by in vitro and in silico studies. Bioorganic Chem.; 2018; 81, pp. 168-174. [DOI: https://dx.doi.org/10.1016/j.bioorg.2018.08.020]
5. Tsong-Min, C. Tyrosinase and tyrosinase inhibitors. J. Biocatal. Biotransformation; 2012; 2, pp. 327-333.
6. Li, J.; Feng, L.; Liu, L.; Wang, F.; Ouyang, L.; Zhang, L.; Hu, X.; Wang, G. Recent advances in the design and discovery of synthetic tyrosinase inhibitors. Eur. J. Med. Chem.; 2021; 224, 113744. [DOI: https://dx.doi.org/10.1016/j.ejmech.2021.113744]
7. Ismaya, W.T.; Rozeboom, H.J.; Weijn, A.; Mes, J.J.; Fusetti, F.; Wichers, H.J.; Dijkstra, B.W. Crystal structure of Agaricus bisporus mushroom tyrosinase: Identity of the tetramer subunits and interaction with tropolone. Biochemistry; 2011; 50, pp. 5477-5486. [DOI: https://dx.doi.org/10.1021/bi200395t]
8. Ismaya, W.T.; Efthyani, A.; Lai, X.; Retnoningrum, D.S.; Rachmawati, H.; Dijkstra, B.W.; Tjandrawinata, R.R. A novel immune-tolerable and permeable lectin-like protein from mushroom Agaricus bisporus. Biochem. Biophys. Res. Commun.; 2016; 473, pp. 1090-1093. [DOI: https://dx.doi.org/10.1016/j.bbrc.2016.04.020]
9. De Luca, L.; Germanò, M.P.; Fais, A.; Pintus, F.; Buemi, M.R.; Vittorio, S.; Mirabile, S.; Rapisarda, A.; Gitto, R. Discovery of a new potent inhibitor of mushroom tyrosinase (Agaricus bisporus) containing 4-(4-hydroxyphenyl) piperazin-1-yl moiety. Bioorganic Med. Chem.; 2020; 28, 115497. [DOI: https://dx.doi.org/10.1016/j.bmc.2020.115497]
10. Xia, L.; Idhayadhulla, A.; Lee, Y.R.; Wee, Y.-J.; Kim, S.H. Anti-tyrosinase, antioxidant, and antibacterial activities of novel 5-hydroxy-4-acetyl-2, 3-dihydronaphtho [1, 2-b] furans. Eur. J. Med. Chem.; 2014; 86, pp. 605-612. [DOI: https://dx.doi.org/10.1016/j.ejmech.2014.09.025]
11. Yu, F.; Pan, Z.; Qu, B.; Yu, X.; Xu, K.; Deng, Y.; Liang, F. Identification of a tyrosinase gene and its functional analysis in melanin synthesis of Pteria penguin. Gene; 2018; 656, pp. 1-8. [DOI: https://dx.doi.org/10.1016/j.gene.2018.02.060] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29496552]
12. Jeon, N.-J.; Kim, Y.-S.; Kim, E.-K.; Dong, X.; Lee, J.-W.; Park, J.-S.; Shin, W.-B.; Moon, S.-H.; Jeon, B.-T.; Park, P.-J. Inhibitory effect of carvacrol on melanin synthesis via suppression of tyrosinase expression. J. Funct. Foods; 2018; 45, pp. 199-205. [DOI: https://dx.doi.org/10.1016/j.jff.2018.03.043]
13. Shoeva, O.Y.; Mursalimov, S.R.; Gracheva, N.V.; Glagoleva, A.Y.; Börner, A.; Khlestkina, E.K. Melanin formation in barley grain occurs within plastids of pericarp and husk cells. Sci. Rep.; 2020; 10, 179. [DOI: https://dx.doi.org/10.1038/s41598-019-56982-y]
14. Hanif, N.; Al-Shami, A.M.A.; Khalid, K.A.; Hadi, H. Plant-based skin lightening agents: A review. J. Phytopharm; 2020; 9, pp. 54-60. [DOI: https://dx.doi.org/10.31254/phyto.2020.9109]
15. Kwon, H.J.; Cho, Y.S. Pharmaceutical Composition for Preventing or Treating Autophagy-Related Diseases, Angiogenic Diseases or Melanin-Related Diseases. U.S. Patent; 9,328,059, 3 May 2016.
16. Momtaz, S.; Lall, N.; Basson, A. Inhibitory activities of mushroom tyrosine and DOPA oxidation by plant extracts. S. Afr. J. Bot.; 2008; 74, pp. 577-582. [DOI: https://dx.doi.org/10.1016/j.sajb.2008.02.005]
17. Hu, H.; Yim, S.; Santhanam, U.; Lyga, J.W. Tyrosinase Inhibitors. Patents; WO2014158943A1, 2 October 2016.
18. Ullah, S.; Son, S.; Yun, H.Y.; Kim, D.H.; Chun, P.; Moon, H.R. Tyrosinase inhibitors: A patent review (2011–2015). Expert Opin. Ther. Pat.; 2016; 26, pp. 347-362. [DOI: https://dx.doi.org/10.1517/13543776.2016.1146253]
19. Amaral, L.M.; Moniz, T.; Leite, A.; Oliveira, A.; Fernandes, P.; Ramos, M.J.; Araújo, A.N.; Freitas, M.; Fernandes, E.; Rangel, M. A combined experimental and computational study to discover novel tyrosinase inhibitors. J. Inorg. Biochem.; 2022; 234, 111879. [DOI: https://dx.doi.org/10.1016/j.jinorgbio.2022.111879]
20. Ha, Y.M.; Park, Y.J.; Lee, J.Y.; Park, D.; Choi, Y.J.; Lee, E.K.; Kim, J.M.; Kim, J.-A.; Park, J.Y.; Lee, H.J. Design, synthesis and biological evaluation of 2-(substituted phenyl) thiazolidine-4-carboxylic acid derivatives as novel tyrosinase inhibitors. Biochimie; 2012; 94, pp. 533-540. [DOI: https://dx.doi.org/10.1016/j.biochi.2011.09.002]
21. Bajpai, P.; Jain, S.; Choubey, A. Thiazolidine, A Versatile ring in the treatment of various Diseases: A Systematic Review. Asian J. Res. Chem.; 2020; 13, pp. 283-286. [DOI: https://dx.doi.org/10.5958/0974-4150.2020.00055.3]
22. Das, A.; Ashraf, M.W.; Banik, B.K. Thione Derivatives as Medicinally Important Compounds. ChemistrySelect; 2021; 6, pp. 9069-9100. [DOI: https://dx.doi.org/10.1002/slct.202102398]
23. Peng, Z.; Wang, G.; Zeng, Q.-H.; Li, Y.; Liu, H.; Wang, J.J.; Zhao, Y. A systematic review of synthetic tyrosinase inhibitors and their structure-activity relationship. Crit. Rev. Food Sci. Nutr.; 2021; 62, pp. 4053-4094. [DOI: https://dx.doi.org/10.1080/10408398.2021.1871724] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33459057]
24. Ullah, S.; Park, Y.; Park, C.; Lee, S.; Kang, D.; Yang, J.; Akter, J.; Chun, P.; Moon, H.R. Antioxidant, anti-tyrosinase and anti-melanogenic effects of (E)-2, 3-diphenylacrylic acid derivatives. Bioorganic Med. Chem.; 2019; 27, pp. 2192-2200. [DOI: https://dx.doi.org/10.1016/j.bmc.2019.04.020] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31027707]
25. Bilgicli, A.T.; Genc Bilgicli, H.; Hepokur, C.; Tüzün, B.; Günsel, A.; Zengin, M.; Yarasir, M.N. Synthesis of (4R)-2-(3-hydroxyphenyl) thiazolidine-4-carboxylic acid substituted phthalocyanines: Anticancer activity on different cancer cell lines and molecular docking studies. Appl. Organomet. Chem.; 2021; 35, e6242. [DOI: https://dx.doi.org/10.1002/aoc.6242]
26. Ohba, M.; Oka, T.; Ando, T.; Arahata, S.; Ikegaya, A.; Takagi, H.; Ogo, N.; Owada, K.; Kawamori, F.; Wang, Q. Discovery and synthesis of heterocyclic carboxamide derivatives as potent anti-norovirus agents. Chem. Pharm. Bull.; 2016; 64, pp. 465-475. [DOI: https://dx.doi.org/10.1248/cpb.c16-00001] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27150478]
27. Ahmed, M.; Fatima, H.; Qasim, M.; Gul, B. Polarity directed optimization of phytochemical and in vitro biological potential of an indigenous folklore: Quercus dilatata Lindl. ex Royle. BMC Complement. Altern. Med.; 2017; 17, 386. [DOI: https://dx.doi.org/10.1186/s12906-017-1894-x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28774308]
28. Rezaei, M.; Mohammadi, H.T.; Mahdavi, A.; Shourian, M.; Ghafouri, H. Evaluation of thiazolidinone derivatives as a new class of mushroom tyrosinase inhibitors. Int. J. Biol. Macromol.; 2018; 108, pp. 205-213. [DOI: https://dx.doi.org/10.1016/j.ijbiomac.2017.11.147]
29. Ashraf, Z.; Rafiq, M.; Seo, S.-Y.; Babar, M.M.; Zaidi, N.-u.-S.S. Synthesis, kinetic mechanism and docking studies of vanillin derivatives as inhibitors of mushroom tyrosinase. Bioorganic Med. Chem.; 2015; 23, pp. 5870-5880. [DOI: https://dx.doi.org/10.1016/j.bmc.2015.06.068] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26204890]
30. Jung, H.J.; Noh, S.G.; Park, Y.; Kang, D.; Chun, P.; Chung, H.Y.; Moon, H.R. In vitro and in silico insights into tyrosinase inhibitors with (E)-benzylidene-1-indanone derivatives. Comput. Struct. Biotechnol. J.; 2019; 17, pp. 1255-1264. [DOI: https://dx.doi.org/10.1016/j.csbj.2019.07.017]
31. Momtaz, S.; Mapunya, B.; Houghton, P.; Edgerly, C.; Hussein, A.; Naidoo, S.; Lall, N. Tyrosinase inhibition by extracts and constituents of Sideroxylon inerme L. stem bark, used in South Africa for skin lightening. J. Ethnopharmacol.; 2008; 119, pp. 507-512. [DOI: https://dx.doi.org/10.1016/j.jep.2008.06.006]
32. Cheminformatics, M. Calculation of molecular properties and bioactivity score. Comput. Softw.; 2018.
33. Dallakyan, S.; Olson, A.J. Small-molecule library screening by docking with PyRx. Chemical Biology; Methods in Molecular Biology; Humana Press: New York, NY, USA, 2015; Volume 1263, pp. 243-250.
34. Amparo, T.R.; Seibert, J.B.; Almeida, T.C.; Costa, F.S.; Silveira, B.M.; da Silva, G.N.; Dos Santos, O.D.; de Souza, G.H. In silico approach of secondary metabolites from Brazilian herbal medicines to search for potential drugs against SARS-CoV-2. Phytother. Res.; 2021; 35, pp. 4297-4308. [DOI: https://dx.doi.org/10.1002/ptr.7097] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33797123]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Heterocyclic nuclei have shown a wide variety of biological activities, highlighting their importance in drug discovery. Derivatives of 2,4-subsituted thiazolidine have a structural similarity with the substrates of tyrosinase enzymes. Hence, they can be used as an inhibitor to compete against tyrosine in the biosynthesis of melanin. This study is focused on design, synthesis, biological activities, and in silico studies of thiazolidine derivatives substituted at positions 2 and 4. The synthesized compounds were evaluated to determine the antioxidant activity and tyrosine inhibitory potential using mushroom tyrosinase. The most potent tyrosinase enzyme inhibitor was compound 3c having IC50 value 16.5 ± 0.37 µM, whereas compound 3d showed maximum antioxidant activity in a DPPH free radical scavenging assay (IC50 = 18.17 µg/mL). Molecular docking studies were conducted using mushroom tyrosinase (PDB ID: 2Y9X) to analyze binding affinities and binding interactions of the protein–ligand complex. Docking results indicated that hydrogen bonds and hydrophobic interactions were mainly involved in the ligand and protein complex. The highest binding affinity was found to be −8.4 Kcal/mol. These results suggest that thiazolidine-4-carboxamide derivatives could serve as lead molecules for development of novel potential tyrosinase inhibitors.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad 04405, Pakistan; Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad 44000, Pakistan
2 Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad 44000, Pakistan
3 Department of Biological Sciences, National University of Medical Sciences, Rawalpindi 43600, Pakistan
4 Department of Chemistry, Allama Iqbal Open University, Islamabad 44310, Pakistan
5 Department of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
6 Department of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna, A-1090 Vienna, Austria
7 Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad 04405, Pakistan